Targeted Therapy Against Hepatocellular Carcinoma

As a frequent solid tumor of the liver, hepatocellular carcinoma (HCC), has a very poor prognosis. It has been the second most common cause of death which leaded by cancer all of the world. With more and more risk factors, such as fatty liver, hepatitis B and C viral infections, alcohol abuse, and metabolic syndrome, HCC represents an increasing incidence and mortality. It is still a challenge for HCC curative treatment. There are no effective therapeutic strategies to meet the clinical need. Despite increasing research about the novel drugs, most of them ultimately fail in Phase III clinical trials. In this review, we provide key point summaries and present research agenda of targeting therapeutic strategies for HCC regarding biomarkers and targeting delivery vehicles. Then, the CAR-T-cell and Bite targeting strategies efficiency are discussed. Finally, this review provides a critical evaluation of the targets and strategies discussed above for personalized treatment of HCC.